Articles and news
Broad but shallow markets in primary care
Uptake of NICE Technology Appraisals
What’s going on at NICE?
The Access Paradox: When NICE Meets NHS Reality
Rethinking the “erosion of in‑house capability” risk
From NICE approval to real‑world access
Why Pharma Must Redesign Its Engagement
Stop haggling over drug price. Start buying productivity.
Cancer innovation meets NHS reality (2025)
Faster uptake for drugs in an established class
Are drugs quietly deciding who gets seen in the NHS?
Reimbursement ≠ patient access
